|
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants Clinical research trials and Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants. Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants clinical trial. Human subjects often obtain the finest healthcare possible for their Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants  Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
For Condition: Candidiasis
Status: No longer recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to compare the safety and effectiveness of 2 treatments to prevent invasive fungal infections (IFI), which are infections caused by yeasts and molds that are common in patients with weak immune systems or transplant patients. AmBisome, a new treatment, will be compared to fluconazole, the traditional treatment for fungal infections caused by the yeast Candida. Treatment will only be given to liver transplant patients who are found to be at high risk for IFI. Liver transplant patients who are at low risk for IFI will be monitored but will receive no study medication. IFIs are found mainly in a high risk group of liver transplant patients, and are not common in those with low risk. If IFI preventive therapy is focused on the high risk group, there may be a lesser chance of Candida becoming resistant (able to grow despite the presence of drugs used to kill it). Treating only the high risk group will also save money.
Details: If you are in the high risk group you will be assigned randomly (like tossing a coin) to receive either AmBisome or fluconazole. If you are in the low risk group, you will not receive any treatment. Both groups will be monitored for IFIs. The study will last for 100 days following your liver transplant.
Eligibility:
Study Type: Interventional, Prevention, Double-Blind
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: You may be eligible for this study if you: - Have had a liver transplant within 5 days of enrollment and agree to receive tacrolimus. Exclusion Criteria: You will not be eligible for this study if you: - Are HIV-positive. - Have a history of invasive fungal infection. - Have received antifungal agents within 14 days prior to your liver transplant. - Are allergic to azoles, amphotericin B, or tacrolimus.
Total Enrollment: 500
Location and Contact Information:
Mary Ellen Bradley
Birmingham, Alabama, 35294
United States
Additional Information:
Study ID Numbers: DMID 98-014; MSG #44
Study Start Date:
Record last reviewed: March 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001107
Other Candidiasis Studies:
1. Fluconazole Prophylaxis of Thrush in AIDS
2. Caspofungin for the Treatment of Non-blood Candida Infections
3. The Safety and Efficacy of Anidulafungin versus Comparator in Patients with Candidemia and Invasive Candidiasis
4. An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
5. Anidulafungin versus Fluconazole in the Treatment of Candidemia
Related Studies:
Other Candidiasis Clinical Trials
Other Alabama Clinical Trials
Other Birmingham Clinical Trials
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
|
|
|
|
|
|
|
|
